Definium Theraputics Inc (DFTX)

[MomsSpaghetti]

Good listen... let's remind our self's of one thing... because the episode title is garbage.

While lysergic acid diethylamide (LSD) itself is not patentable due to its long-standing existence, MindMed has developed MM-120, a proprietary, pharmaceutically optimized form of LSD. To protect their innovation, MindMed has secured patents on specific formulations and delivery methods of MM-120. Notably, in July 2024, the United States Patent and Trademark Office (USPTO) issued a patent covering the MM-120 Orally Disintegrating Tablet (ODT) formulation. This patent includes claims on the pharmaceutical formulation, manufacturing methods, and treatment methods for MM-120 ODT, extending MindMed’s intellectual property protection through 2041. ?

Additionally, MindMed holds exclusive rights to Catalent’s Zydis ODT fast-dissolve technology for all salt and polymorphic forms of lysergide (LSD) for pharmaceutical use in several regions, including the United States, the United Kingdom, the European Union, Switzerland, Israel, and Canada. ? This advanced formulation aims to offer rapid absorption, improved bioavailability, and reduced gastrointestinal side effects, potentially providing a unique clinical profile for MM-120.

By focusing on these proprietary formulations and delivery technologies, MindMed establishes a competitive advantage and safeguards its developments in the therapeutic application of LSD derivatives.

Having said that... we are moving into phase 3 and with lots of positive push from prior trials. The data proves there is something here. Risk mostly has been removed.

We are going to rebound. MindMed is a winner in this space. It's only a matter of time.